GigaDevice Strengthens Global Presence at Embedded World 2026, Showcasing System-Level Innovations for Humanoid Robotics, Industry, and Edge AI
9.3.2026 08:00:00 CET | Business Wire | Press release
Wide range of demonstrations on display at Hall 5, 5-129 throughout the March 10-12 show
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced its participation at Embedded World 2026 (Hall 5, Booth 5-129), with the strong presence at the show demonstrating the company’s commitment to the global market and the strategic emphasis that it has placed on the EMEA region, reinforcing its ambition to empower customers with advanced embedded solutions.
“Embedded World is a cornerstone of our global engagement strategy,” said Dr. Reiner Jumpertz, GigaDevice VP and General Manager in the EMEA region. “This year, we are not only showcasing our technical excellence but also highlighting our evolution into a system-level enabler, a trusted partner that supports customers in building smarter, more connected applications.”
“By combining our high-performance GD32 MCUs, industry-proven Flash memory, and advanced analog and sensor technologies, we are providing the foundational technology that helps our EMEA customers go from concept to mass production across multiple high-growth markets.”
At the exhibition, GigaDevice will demonstrate its latest system-level capabilities and its role as a long-term solution partner for global industrial leaders, with live demonstrations across four high-growth application sectors.
Empowering the Next Generation of Humanoid Robotics with System-Level Intelligence
GigaDevice is driving innovation in humanoid robotics, enabling the next generation of highly dexterous and intelligent robots. The company provides a comprehensive solution that combines high-performance GD32 MCUs, including the GD32H75E, GD32G5, and GD32F5 series, with high-speed Flash memory and advanced analog products. This complete system-level offering delivers the computing power, real-time responsiveness, and seamless integration required for complex motion control, sensor fusion, and environmental perception in humanoid robotic platforms.
Advancing Industrial Automation with High-Performance EtherCAT® System Solutions
GigaDevice is accelerating innovation in industrial automation, empowering the transformation toward Industry 4.0 with advanced connectivity and precise motion control. The company provides a complete EtherCAT® Servo Drive SubDevice system solution, built around high-performance GD32H75E Cortex®‑M7 MCUs, to meet the demanding requirements of modern industrial applications. This system-level solution delivers high-precision motion control and real-time communication through the CiA 402 protocol and TwinCAT®, enabling efficient, synchronized, and intelligent control across complex automation networks.
Driving the Future of Automotive Electronics with Scalable MCU and Memory Solutions
GigaDevice is a leading force in automotive memory, with cumulative Flash shipments exceeding 300 million units worldwide. Building on this strong foundation, the company is expanding its automotive MCU portfolio, highlighted by the second-generation GD32A7 series. This high-performance automotive MCU reached ISO26262 ASIL B security level and meets the information security standard of Evita Full+SM2/3/4.
It is suitable for motor control and domain-based vehicle architectures, and is widely adopted in body domain control, 400 V battery management systems (BMS), and adaptive driving beam (ADB) lighting systems.
Enabling Edge Intelligence and Matter Connectivity through RISC‑V and High‑Performance MCU
GigaDevice presents an AI-powered voice recognition demo on the GD32H7 series, delivering instant wake-up and keyword detection for natural voice interaction. With support for customizable, multi-language voice commands and on-device AI processing, the demo highlights how embedded systems can enable fast, intuitive, and low-latency voice control for next-generation smart applications. In parallel, GigaDevice presents a Matter wireless connectivity solution based on the GD32VW553 wireless 160 MHz MCU, integrating Wi‑Fi and Bluetooth to support secure and seamless communication across smart home and IoT ecosystems. The solution further incorporates the newly introduced GD30TSHT30 temperature and humidity sensor, enabling precise environmental monitoring and enhancing the overall reliability and intelligence of connected devices.
Visit GigaDevice at Embedded World 2026, held from March 10–12 at the Nuremberg Messe. Experience all demonstrations in Hall 5, Stand 5‑129.
*GigaDevice, GD32, and their logos are trademarks, or registered trademarks of GigaDevice Semiconductor Inc. Other names and brands are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260309380811/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom